Bachem highlights peptide growth, shares anchored on SIX Swiss Exchange

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 12:21.

Bachem Holding AG (CH0012530207) is a Swiss-listed biotech supplier with its shares traded on the SIX Swiss Exchange in Zurich. The company is best known for industrial-scale peptide and oligonucleotide manufacturing for pharmaceutical and biotech clients, supporting research and commercial therapies.

Analyst lens on Bachem today

Analyst coverage of Bachem generally focuses on its position as a specialized supplier in the global pharmaceutical value chain. Houses such as UBS or Vontobel typically assess the stock through revenue growth in custom manufacturing projects and capacity utilization at its facilities, along with margin trends over multi-year horizons.

Where consensus data is available, rating distributions for Bachem often show a mix of Buy, Hold and occasional Sell recommendations, reflecting differing views on valuation versus growth potential. Price targets from Swiss and international brokers tend to be benchmarked against peers in contract development and manufacturing services rather than large-cap pharma groups.

How Bachem fits in the biotech supply chain

Bachem operates in a niche of the healthcare sector known as contract development and manufacturing, supplying active ingredients and related services to drug developers. This puts the stock conceptually alongside peers such as Lonza Group or Siegfried, which also provide outsourced manufacturing solutions to pharmaceutical customers.

The business model emphasizes long-term customer relationships, multi-year production contracts and compliance with stringent regulatory standards. Investors typically watch indicators such as order backlog, new project wins and regulatory inspections to gauge operational momentum and risk in this type of stock.

The product behind the Bachem stock

Bachem’s core business revolves around the development and manufacture of peptides, which are short chains of amino acids used as active pharmaceutical ingredients in various therapeutic areas. The company supplies custom peptide synthesis and related services to research organizations and pharmaceutical firms worldwide.

Where the Bachem shares trade

The Bachem shares (CH0012530207) are listed on the SIX Swiss Exchange in Zurich, where they trade in Swiss francs. As of 2026-06-30, 12:21, the current price information for the stock should be checked directly on the SIX platform or a live quote service for precise levels.

Disclaimer: This text provides general information on the Bachem shares and does not constitute investment advice, a buy or sell recommendation, or a price target. Retail investors should consider their own financial situation and consult independent sources before making investment decisions.